Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

Share this content:
Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
The following article features coverage from the American Society of Clinical Oncology (ASCO) 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) compared with those not receiving nimotuzumab, according to data presented at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.1

Nimotuzumab in a humanized antibody against the epidermal growth factor receptor (EGFR) and inhibits the binding of the ligand, EGF, to EGFR.

The phase 3 study randomly assigned patients with stage III/IV locally advanced SCCHN to receive nimotuzumab or placebo. All patients received concurrent radiotherapy and cisplatin.

All patients received radical radiotherapy (66-70 Gy) with weekly cisplatin 30 mg/m2. Patients in the nimotuzumab arm of the arm also received weekly nimotuzumab 200 mg.

The study required an enrollment of 536 patients for a superiority margin of 12% assuming a progression-free survival (PFS) of 60% with an 80% power and an alpha of 0.05.

Patients (n = 536) were randomly assigned equally in both arms. At a median follow up of 33 months, median PFS was significantly longer in patients receiving nimotuzumab (58.9% vs 49.5% for placebo; P = .022). With a hazard ratio of 0.74, patients receiving nimotuzumab were at a 26% reduced risk for progression.

Median duration of PFS was also longer for patients receiving nimotuzumab: 60.3 months compared with 21 months for patients receiving placebo.

The report also indicated that locoregional control and disease-free survival were significant with nimotuzumab (hazard ratio: 0.75; P = .030).

Overall survival trended towards significance with nimotuzumab (HR: 0.85; P = .222).

Except for mucositis, grade 3/4 adverse events were similar across the two arms. Incidence of mucositis was higher with nimotuzumab (66.7% vs 55.8% for placebo; P = .010).

According to the report, nimotuzumab given concurrently with radiotherapy and cisplatin was superior to the combination of radiotherapy and cisplatin in the treatment of locally advanced SCCHN.

Read more of Cancer Therapy Advisor's coverage of the American Society of Clinical Oncology (ASCO) 2018 meeting by visiting the conference page.

Reference

  1. Patil VM, Noronha V, Joshi A, et al. Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2018: 36, (suppl; abstr 6000). Presented at 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, IL.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs